Related Experiment Videos
Antenatal dexamethasone and decreased birth weight
S L Bloom1, J S Sheffield, D D McIntire
1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. steven.bloom@email.swmed.edu
Obstetrics and Gynecology
|March 29, 2001
Summary
Antenatal dexamethasone treatment for fetal lung maturation is linked to lower infant birth weights. This study confirms a significant association between this prenatal therapy and reduced birth weight, even after accounting for gestational age.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Research
- Pharmacology
Background:
- Antenatal corticosteroid therapy, such as dexamethasone, is used to accelerate fetal lung maturation.
- Potential effects on fetal growth, specifically birth weight, require thorough investigation.
Purpose of the Study:
- To evaluate the impact of antenatal dexamethasone on birth weight, adjusted for gestational age.
- To determine if dexamethasone treatment is associated with decreased birth weight in singleton infants.
Main Methods:
- Comparison of birth weights of dexamethasone-treated infants with a large overall obstetric population.
- Utilized frequency-matched untreated infant controls (3:1 ratio).
- Included a historical cohort of infants treated before widespread corticosteroid use.
Main Results:
- Dexamethasone-exposed infants showed significantly lower birth weights compared to both the overall population and matched controls (P <.001).
- Birth weight deficits ranged from 12g to 161g depending on gestational age at delivery.
- The observed reduction in birth weight was statistically significant across multiple gestational age groups.
Conclusions:
- Antenatal dexamethasone administration for fetal lung maturation is associated with diminished birth weight.
- The findings highlight a potential trade-off between accelerated lung maturation and fetal growth.
- Further research may explore optimal timing and dosage to mitigate growth effects.